MTA1-Targeted Chemopreventive, Interceptive and Therapeutic Options in Prostate Cancer

This grand round has already taken place.

Metastasis-associated protein 1 (MTA1), an epigenetic regulator, plays an important role in prostate cancer progression and metastasis. To investigate the exact role of MTA1 in prostate cancer tumorigenesis and progression to metastasis, we have established MTA1 knockdown cells in various prostate cancer cells lines and performed mechanistic studies in vitro. To test MTA1-targeted strategies for chemoprevention and therapy, we developed appropriate mouse models, namely prostate-specific MTA1-knocked in (MTA1-tg) and MTA1-tg on the background of prostate-specific Pten heterozygosity and loss. Chemopreventive pre-clinical studies were designed using dietary interventions with stilbenes’ supplementations while therapeutic strategies involved combinatorial approaches. Our results demonstrated the contribution of MTA1 in advanced prostate cancer and bone metastasis. Increased levels of oncogenic MTA1-guided molecules identified by ChiP-Seq, including specific MTA1-associated miRNAs may serve as prognostic and predictive biomarkers. We propose a potential for MTA1-targeted strategies in prostate cancer chemoprevention, interception, and therapy.

• Streams
• Additional Info
• Speakers
• Accreditation
• Disclosure

Please contact the Grand Round coordinator listed below:

Nancy Strein
Department: Pathology
Phone: (631) 444-3000
Email: nancy.strein@stonybrookmedicine.edu